Form 4: Krystal Biotech President Sells Shares via 10b5-1 Plan

Suma Krishnan, President of R&D at Krystal Biotech, sold 25,178 shares of common stock on June 4, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Summary

• Suma Krishnan, President of R&D at Krystal Biotech, Inc. (KRYS), executed a series of stock sales on June 4, 2026.
• A total of 25,178 shares were sold at prices ranging from $300.75 to $311.65 per share.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on September 4, 2025.
• Following these transactions, the reporting person maintains direct ownership of 1,378,155 shares, in addition to indirect holdings through family trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were pre-planned and represent a standard liquidity event for an executive rather than a reaction to company-specific news.

Positives

• The sales were executed under a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without concerns regarding non-public information.
• The reporting person retains a significant equity stake of over 1.37 million shares, signaling continued alignment with long-term company performance.

Negatives

• The sale represents a reduction in the direct equity position held by a key executive.

Risks

• The Rule 10b5-1 plan is scheduled to terminate on December 4, 2026, which may lead to further periodic selling activity by the executive until that date.

Future Outlook

The reporting person continues to operate under a Rule 10b5-1 trading plan that remains in effect until December 4, 2026, or until the completion of the sale of all shares subject to the plan.

Management Comments

• The reporting person disclaims beneficial ownership of shares held by her spouse except to the extent of her pecuniary interest.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a common practice in the biotech sector, often used by executives to diversify personal holdings while avoiding regulatory scrutiny related to timing.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers in the S&P 500 and NASDAQ-listed biotech firms to manage liquidity.
• The volume of shares sold relative to the total holdings is consistent with typical executive diversification strategies.

Related Party Transactions

• The reporting person's spouse, Krish S. Krishnan, also holds shares and files separate reports.
• Shares are held in the Krishnan Spousal Trust and the Krishnan Family Trust.

Stakeholder Impact

• Minimal impact on shareholders as the sales were conducted through a pre-arranged, automated plan.

Next Steps

• Continued execution of the Rule 10b5-1 trading plan through December 4, 2026.

Key Dates

Keywords

Krystal Biotech, KRYS, Insider Trading, Form 4, Biotechnology, Rule 10b5-1